Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Short Interest Down 63.2% in December

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) saw a significant decrease in short interest in December. As of December 15th, there was short interest totaling 45,540 shares, a decrease of 63.2% from the November 30th total of 123,591 shares. Based on an average daily trading volume, of 218,008 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.0% of the company's shares are sold short. Currently, 0.0% of the company's shares are sold short. Based on an average daily trading volume, of 218,008 shares, the days-to-cover ratio is currently 0.2 days.Shionogi & Co., Ltd. Unsponsored ADR Stock Up 1.9%Shares of SGIOY stock traded up $0.17 on Friday, reaching $9.05. 58,010 shares of the company's stock traded hands, compared to its average volume of 102,712. The company has a market capitalization of $15.40 billion, a P/E ratio of 14.14, a price-to-earnings-growth ratio of 2.10 and a beta of 0.20. Shionogi & Co., Ltd. Unsponsored ADR has a 12-month low of $6.71 and a 12-month high of $9.23. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.74 and a current ratio of 6.44. The business's 50 day moving average price is $8.49 and its two-hundred day moving average price is $8.59. Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last released its earnings results on Monday, October 27th. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.02. The company had revenue of $740.85 million for the quarter, compared to analysts' expectations of $742.35 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 11.90% and a net margin of 39.53%. On average, equities analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 earnings per share for the current year. Shionogi & Co., Ltd. Unsponsored ADR Company Profile (Get Free Report)Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders. The company's product portfolio spans both established and innovative therapies.Read MoreFive stocks we like better than Shionogi & Co., Ltd. Unsponsored ADRA month before the crashWall Street Stockpicker Names #1 Stock of 2026Shots officially fired…Washington prepares for war“$6.6 Trillion Of Customer Bank Deposits At Risk”This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Shionogi & Co., Ltd. Unsponsored ADR Right Now?Before you consider Shionogi & Co., Ltd. Unsponsored ADR, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shionogi & Co., Ltd. Unsponsored ADR wasn't on the list.While Shionogi & Co., Ltd. Unsponsored ADR currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here